| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/30/2002 | CN1333017A Application of rhein in treating insulin resistance |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342533 Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders |
| 01/29/2002 | US6342532 Antiarthritic, hypotensive agents for urogenital and glandular disorders; calcium channels modulators |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342512 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342500 Antidiabetic agents |
| 01/29/2002 | US6342498 Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists |
| 01/29/2002 | US6342489 Treatment of iron deficiency with ferric salt of bis hemisuccinylursodeoxycholic acid |
| 01/29/2002 | US6342245 Compositions of lipid lowering agents |
| 01/29/2002 | US6342227 Administration of insulin like growth factor (igf-i) for delaying clinical onset of diabetes |
| 01/29/2002 | CA2031368C Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006483A1 Novel physiologically active peptide and use thereof |
| 01/24/2002 | WO2002006466A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/24/2002 | WO2002006349A1 Gel compositions containing metronidazole |
| 01/24/2002 | WO2002006316A2 Alpha-msh related compounds and methods of use |
| 01/24/2002 | WO2002006307A1 Reduced fk228 and use thereof |
| 01/24/2002 | WO2002006299A2 Therapeutic uses for aminosterol compounds |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006286A2 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006276A1 Beta3 adrenergic agonists |
| 01/24/2002 | WO2002006274A1 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006261A1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 01/24/2002 | WO2002006258A1 Azolidines as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006250A1 Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006245A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006231A1 Serotonin reuptake inhibitors |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006221A2 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006218A2 STABILIZED 1α-HYDROXY VITAMIN D |
| 01/24/2002 | WO2002006210A1 Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006189A2 Aniline derivatives |
| 01/24/2002 | WO2002005857A2 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | WO2002005847A1 Kubouchi's method of intramuscularly injecting mixture of drug with patient's blood and kubouchi's substances produced thereby |
| 01/24/2002 | WO2002005841A1 Treatment of glycogen storage disease type ii |
| 01/24/2002 | WO2002005840A1 Medicinal compositions for promoting fixation of transplanted cells |
| 01/24/2002 | WO2002005834A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 01/24/2002 | WO2002005830A2 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| 01/24/2002 | WO2002005828A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | WO2002005815A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | WO2002005807A1 Treatment of eating disorders using carboxyalkylethers |
| 01/24/2002 | WO2002005795A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2001060814A3 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001056405A3 A method for maintaining or improving the synthesis of mucins |
| 01/24/2002 | WO2001052878A3 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 01/24/2002 | WO2001051071A3 Transepithelial delivery of glp-1 derivatives |
| 01/24/2002 | WO2001047506A3 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032157A3 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001025436A3 Endozepine-like polypeptides and polynucleotides encoding same |
| 01/24/2002 | WO2001023387A3 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2000071107A8 New pharmaceutical combinations for nos inhibitors |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010203 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| 01/24/2002 | US20020010195 Mitochondria protecting agents for treating mitochondria associated diseases |
| 01/24/2002 | US20020010192 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010187 5-((4-(3-methyl-4-oxo-3,4-dihydro-2 -quinazolinyl)methoxy)phenylmethyl)thiazolidine-2 ,4-dione or a pharmaceutically acceptable salt thereof |
| 01/24/2002 | US20020010185 Anticarcinogenic agents |
| 01/24/2002 | US20020010183 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 01/24/2002 | US20020010171 New compounds, their preparation and use |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010165 Treating the hypercalcemia associated with malignant or neoplastic cells with an effective amount of a hypocalcemic vitamin D compound having a hydrocarbon moiet at the 24 position |
| 01/24/2002 | US20020010160 Therapeutic agents |
| 01/24/2002 | US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases |
| 01/24/2002 | US20020010153 Oral delivery of macromolecules |
| 01/24/2002 | US20020009776 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/24/2002 | US20020009740 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 01/24/2002 | US20020009510 Plant extracts for the treatment of increased bone resorption |
| 01/24/2002 | US20020009496 Spraying a suspension of microionized fenofibrate and polyvinylpyrrolidone onto an inert hydrosoluble carrier; immediate-release; improved dissolution |
| 01/24/2002 | US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/24/2002 | US20020009481 Substance with antiobese and cumulative visceral fat-reducing actions and use thereof |
| 01/24/2002 | US20020009450 Administering antagonist to surface receptors |
| 01/24/2002 | DE19963234A1 New N,N-disubstituted piperazine and diazacycloheptane derivatives useful in treatment of hyperlipidemia, atherosclerosis, diabetes mellitus, adiposity and pancreatitis |
| 01/24/2002 | DE10034233A1 Tocotrienolchinon-Cyclisierungsprodukte Tocotrienolquinone cyclization products |
| 01/24/2002 | CA2419626A1 Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders |
| 01/24/2002 | CA2416693A1 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | CA2416667A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
| 01/24/2002 | CA2416452A1 Novel proteins and nucleic acids encoding same |
| 01/24/2002 | CA2416248A1 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | CA2416245A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | CA2415938A1 Alpha-msh related compounds and methods of use |